Results 101 to 110 of about 43,876 (313)

Unprecedented Combination of Rare Degenerative Pathologies in an Octogenarian Ex‐Football Player

open access: yesNeuropathology, EarlyView.
ABSTRACT A 79‐year‐old former professional football player presented with language deficits and cognitive changes. A year later, he had difficulty completing sentences, and 3 years after onset, was reduced to one‐word answers. He developed severe apathy and agitation, and became more impulsive.
Shelley L. Forrest   +6 more
wiley   +1 more source

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. [PDF]

open access: yes, 2015
OBJECTIVE: The authors examined research on effects, costs, and patient and caregiver views of pharmacological management strategies for Lewy body dementia.
Cambridge, Victoria   +9 more
core   +2 more sources

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients

open access: yesClinical Interventions in Aging, 2018
Nan Zhang,1,2 Marc L Gordon3,4 1Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Tianjin, People’s Republic of China; 2Department of Neurology and Neurosurgery, Tianjin Medical University ...
Zhang N, Gordon ML
doaj  

Accelerated Intermittent Theta Burst Stimulation Combined with Balance Training Improves Balance in an Individual with Corticobasal Syndrome

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Karishma R. Ramdeo   +6 more
wiley   +1 more source

Psychiatric‐onset neuronal intranuclear inclusion disease in a psychiatry‐based dementia‐enriched cohort in Japan

open access: yesPsychiatry and Clinical Neurosciences, EarlyView.
Aim A GGC repeat expansion in the 5′ untranslated region of NOTCH2NLC is a genetic cause of Neuronal Intranuclear Inclusion Disease (NIID) that exhibits cognitive, motor, and autonomic dysfunction. Our objective is to determine whether there are undiagnosed NIID cases in a psychiatry‐based dementia‐enriched cohort and to identify their clinical ...
Tesshin Miyamoto   +15 more
wiley   +1 more source

Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. [PDF]

open access: yes, 2019
Mood disorders are highly prevalent and are the leading cause of disability worldwide. The neurobiological mechanisms underlying depression remain poorly understood, although theories regarding dysfunction within various neurotransmitter systems have ...
Dulawa, Stephanie C, Janowsky, David S
core  

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure [PDF]

open access: yes, 2015
The clinical syndrome of heart failure is one of the leading causes of hospitalisation and mortality in older adults. An association between cognitive impairment and heart failure is well described but our understanding of the relationship between the ...
Cannon, Jane A.   +2 more
core   +4 more sources

Changes in Neuroimmune and Neuronal Death Markers after Adolescent Alcohol Exposure in Rats are Reversed by Donepezil

open access: yesScientific Reports, 2019
Adolescent intermittent ethanol (AIE) exposure diminishes neurogenesis and dendritic spine density in the dentate gyrus. The cholinesterase inhibitor, donepezil (Aricept), reverses AIE effects on dendritic spines, possibly by interacting with ...
H. Swartzwelder   +5 more
semanticscholar   +1 more source

Changes in the cortical GABAergic inhibitory system with ageing and ageing‐related neurodegenerative diseases

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend With ageing and age‐related neurodegenerative diseases, the amount of GABA and GABAergic inhibition as well as the modulation (indicated by sine wave) of GABAergic inhibition is reduced, whereas excitation is increased. In many parts of the brain, this leads to a mismatch of facilitatory (green neurons) and inhibitory (red ...
Wolfgang Taube, Benedikt Lauber
wiley   +1 more source

Does treatment with donepezil improve memory for patients with mild cognitive impairment? [PDF]

open access: yes, 2006
Donepezil (Aricept) has potential benefit in delaying risk of progression to Alzheimer's disease in the first year of treatment, but this benefit is not seen at 3 years.
Martin, Sandra I., Stiles, Melissa M.
core  

Home - About - Disclaimer - Privacy